Mesoblast (MESO) Net Cash Flow Growth (1y) (2017 - 2023)
Mesoblast (MESO) Net Cash Flow Growth (1y) (2017 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.39 Bn | 467.60 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 122.08 Bn | 114.83 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.97 Bn | 50.78 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn | 53.46% |
| 10 | Mesoblast | 18.88 Bn | 18.75 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 239.23% |
| Mar 31, 2023 | -3.69% |
| Dec 31, 2022 | 12.66% |
| Sep 30, 2022 | 226.21% |
| Jun 30, 2022 | 24.43% |
| Mar 31, 2022 | -122.35% |
| Dec 31, 2021 | 33.25% |
| Sep 30, 2021 | 5.80% |
| Jun 30, 2021 | -131.69% |
| Mar 31, 2021 | 491.98% |
| Dec 31, 2020 | -168.33% |
| Sep 30, 2020 | -36.97% |
| Jun 30, 2020 | 438.73% |
| Mar 31, 2020 | -208.58% |
| Dec 31, 2019 | 112.01% |
| Sep 30, 2019 | -190.44% |
| Jun 30, 2019 | 7.95% |
| Mar 31, 2019 | -155.51% |
| Dec 31, 2018 | 241.89% |
| Sep 30, 2018 | 0.33% |